8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
Apr 28, 2026·SEC
Translational Development Acquisition Corp.(TDAC)Earnings, Financials & Key Ratios
TDAC•NASDAQ•Banking & Credit
29.1× P/E·Price updated Jun 19, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutTranslational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.Show more
- Net Interest Income$0-100.0%
- Total Revenue$0-100.0%
- Net Income$6M+9059.7%
- Return on Equity3.7%+4484.5%
- Net Interest Margin0%-100.0%
- ROA3.57%+4493.3%
- Equity / Assets96.38%
- Book Value per Share10.15-75.6%
TDAC Key Insights
Translational Development Acquisition Corp. (TDAC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Well capitalized: 96.4% equity/assets
- ✓Trading near 52-week high
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 1.8%
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TDAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TDAC Price & Volume
Translational Development Acquisition Corp. (TDAC) stock price & volume — 10-year historical chart
Loading chart...
TDAC Growth Metrics
Translational Development Acquisition Corp. (TDAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM339.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-18.54%
Return on Capital
10 Years-316.64%
5 Years-316.64%
3 Years-316.64%
Last Year-0.53%
TDAC Recent Earnings
Translational Development Acquisition Corp. (TDAC) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.06
—
Rev
—
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.07
—
Rev
—
—
Q4 2021
Sep 30, 2021Metric
Actual
Est
EPS
$0.93
—
Rev
$32M
—
Q3 2021
Aug 16, 2021Metric
Actual
Est
EPS
$0.23
—
Rev
$32M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.06 | — |
| Q2 2026 | Mar 16, 2026 | $0.07 | — |
| Q4 2021 | Sep 30, 2021 | $0.93 | $32M |
| Q3 2021 | Aug 16, 2021 | $0.23 | $32M |
Based on last 12 quarters of dataView full earnings history →
TDAC Peer Comparison
Translational Development Acquisition Corp. (TDAC) competitors in Healthcare and life sciences SPACs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HCAI | 8.75M | 7.77 | -0.21 | -83.94% | -262.32% | 0.01 | ||
 GS | 348.27B | 1096.56 | 21.37 | -1.38% | 13.73% | 13.58% | 4.88 | |
 MS | 355.51B | 223.17 | 21.88 | 11.48% | 14.66% | 15.3% | 4.22 | |
 JPM | 908.57B | 325.22 | 16.22 | 3.31% | 20.35% | 15.95% | 2.60 | |
 EVR | 14.72B | 371.72 | 26.46 | 29.49% | 15.26% | 29.32% | 0.50 | |
 LAZ | 4.16B | 44.30 | 20.41 | 3.25% | 7.5% | 26.7% | 2.61 | |
 PJT | 3.76B | 155.47 | 23.27 | 14.77% | 10.32% | 20.08% | 0.41 |
Compare TDAC vs Peers
Translational Development Acquisition Corp. (TDAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TDAC Income Statement
Translational Development Acquisition Corp. (TDAC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Net Interest Income | 0 | 0 | 125.35K | 0 | 1.87M |
NII Growth % | - | - | - | -100% | 0% |
Net Interest Margin % | 0% | 0% | 0.07% | 0% | 1.02% |
Interest Income | 0 | 0 | 0 | 0 | 1.87M |
Interest Expense | 0 | 0 | 508.56K | 0 | 0 |
Loan Loss Provision | 0 | 0 | -187.69K | 0 | 0 |
Non-Interest Income | 0 | 0 | 1.07M | 0 | -1.87M |
Non-Interest Income % | - | - | 100% | - | - |
Total Revenue | 0▲ 0% | 0▲ 0% | 1.07M▲ 0% | 0▼ 100.0% | 0▲ 0% |
Revenue Growth % | - | - | - | -100% | 0% |
Non-Interest Expense | 70.66K | 485.55K | 196.36K | 944.54K | 878.29K |
Efficiency Ratio | - | - | 18.42% | - | - |
Operating Income | -70.66K▲ 0% | -485.55K▼ 587.1% | -196.36K▲ 59.6% | -944.54K▼ 381.0% | -878.29K▲ 0% |
Operating Margin % | - | - | -18.42% | - | - |
Operating Income Growth % | - | -587.14% | 59.56% | -381.03% | - |
Pretax Income | -70.66K▲ 0% | -485.55K▼ 587.1% | -71.01K▲ 85.4% | 6.36M▲ 9059.7% | 6.21M▲ 0% |
Pretax Margin % | - | - | -6.66% | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
Net Income | -70.66K▲ 0% | -485.55K▼ 587.1% | -71.01K▲ 85.4% | 6.36M▲ 9059.7% | 6.21M▲ 0% |
Net Margin % | - | - | -6.66% | - | - |
Net Income Growth % | - | -587.14% | 85.37% | 9059.65% | 339.67% |
Net Income (Continuing) | -70.66K | -485.55K | -71.01K | 6.36M | 6.21M |
EPS (Diluted) | -0.02▲ 0% | -0.12▼ 589.7% | -0.02▲ 86.5% | 0.37▲ 2384.0% | 0.36▲ 0% |
EPS Growth % | - | -589.66% | 86.5% | 2383.95% | -18.54% |
EPS (Basic) | -0.02 | -0.12 | -0.02 | 0.37 | - |
Diluted Shares Outstanding | 4.05M | 4.05M | 4.05M | 17.25M | 17.25M |
TDAC Balance Sheet
Translational Development Acquisition Corp. (TDAC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash & Short Term Investments | 2.23K | 2.02K | 438.17K | 29.79K | 136.82K |
Cash & Due from Banks | 2.23K | 2.02K | 438.17K | 29.79K | 24.63K |
Short Term Investments | 0 | 0 | 0 | 0 | 0 |
Total Investments | 0 | 0 | 174.35M | 181.66M | 183.27M |
Investments Growth % | - | - | - | 4.19% | 8.22% |
Long-Term Investments | 0 | 0 | 174.35M | 181.66M | 722.85M |
Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
Goodwill & Intangibles | 0 | 0 | 21.63T | 0 | 0 |
Goodwill | 0 | 0 | 9.06T | 0 | 0 |
Intangible Assets | 0 | 0 | 12.57T | 0 | 0 |
PP&E (Net) | 0 | 0 | 0 | 0 | 0 |
Other Assets | 383.01K | 0 | -21.63T | 0 | 0 |
Total Current Assets | 54.23K | 2.02K | 650.23K | 39.47K | 75.32K |
Total Non-Current Assets | 383.01K | 0 | 174.35M | 181.66M | 183.27M |
Total Assets | 437.24K▲ 0% | 2.02K▼ 99.5% | 175M▲ 8659008.3% | 181.7M▲ 3.8% | 183.35M▲ 0% |
Asset Growth % | - | -99.54% | 8659008.31% | 3.83% | 289360.89% |
Return on Assets (ROA) | -16.16% | -221.08% | -0.08% | 3.57% | 3.44% |
Accounts Payable | 0 | 1.25K | 16.19K | 0 | 0 |
Total Debt | 259K | 347.5K | 347.5K | 200K | 500K |
Net Debt | 256.77K | 345.48K | -90.67K | 170.21K | 475.37K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Short-Term Debt | 259K | 347.5K | 6.11T | 200K | 500K |
Other Liabilities | 0 | 0 | 6.04M | 6.04M | 6.04M |
Total Current Liabilities | 459.39K | 509.68K | 210.3K | 544.07K | 861.09K |
Total Non-Current Liabilities | 0 | 0 | 6.04M | 6.04M | 6.04M |
Total Liabilities | 459.34K | 509.68K | 6.25M | 6.58M | 6.9M |
Total Equity | -22.11K▲ 0% | -507.66K▼ 2196.3% | 168.75M▲ 33341.4% | 175.12M▲ 3.8% | 176.45M▲ 0% |
Equity Growth % | - | -2196.26% | 33341.43% | 3.77% | 64357.36% |
Equity / Assets (Capital Ratio) | -5.06% | -25119.15% | 96.43% | 96.38% | 96.24% |
Return on Equity (ROE) | - | - | -0.08% | 3.7% | 3.57% |
Book Value per Share | -0.01 | -0.13 | 41.67 | 10.15 | 10.23 |
Tangible BV per Share | -0.01 | -0.13 | -5340906.48 | 10.15 | 10.23 |
Common Stock | 466 | 466 | 18.33B | 181.66M | 183.27M |
Additional Paid-in Capital | 24.53K | 24.53K | 0 | 0 | 0 |
Retained Earnings | -47.11K | -532.66K | -5.6M | -6.54M | -6.82M |
Accumulated OCI | 0 | 0 | 16.88B | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
TDAC Cash Flow Statement
Translational Development Acquisition Corp. (TDAC) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -97.16K | -204 | -851.45K | -608.39K | -681.97K |
Operating CF Growth % | - | 99.79% | -417275.49% | 28.55% | -63.88% |
Net Income | -71 | -485.55K | -71.01K | 6.36M | 6.21M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -97.02K | 482.34K | -120.63K | -7.31M | -7.15M |
Working Capital Changes | -75 | 3.01K | -659.81K | 336.15K | 258.88K |
Cash from Investing | 0 | 0 | -174.22M | 0 | 0 |
Purchase of Investments | 0 | 0 | -174.22M | 0 | 0 |
Sale/Maturity of Investments | 0 | 0 | 0 | 0 | 0 |
Net Investment Activity | 0 | 0 | -174.22M | 0 | 0 |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Other Investing | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 99.39K | 0 | 175.51M | 200K | 500K |
Dividends Paid | 0 | 0 | -125.35K | 0 | -1.84M |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Stock Issued | -125.61K | 0 | 169.05M | 0 | 0 |
Net Stock Activity | -125.61K | 0 | 169.05M | 0 | 0 |
Debt Issuance (Net) | 225K | 0 | -393.46K | 200K | 500K |
Other Financing | 0 | 0 | 6.98M | 0 | 1.84M |
Net Change in Cash | 2.23K▲ 0% | -204▼ 109.2% | 436.15K▲ 213900.5% | -408.39K▼ 193.6% | -181.97K▲ 0% |
Exchange Rate Effect | 0 | 0 | 0 | 0 | 0 |
Cash at Beginning | 0 | 2.23K | 2.02K | 438.17K | 29.79K |
Cash at End | 2.23K | 2.02K | 438.17K | 29.79K | 24.63K |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Income Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Free Cash Flow | -145▲ 0% | -204▼ 40.7% | -851.45K▼ 417275.5% | -608.39K▲ 28.5% | -681.97K▲ 0% |
FCF Growth % | - | -40.69% | -417275.49% | 28.55% | 37.03% |
TDAC Banking Ratios
Translational Development Acquisition Corp. (TDAC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | - | -0.08% | 3.7% | 3.57% |
Return on Assets (ROA) | -221.08% | -0.08% | 3.57% | 3.44% |
Net Interest Margin | 0% | 0.07% | 0% | 1.02% |
Efficiency Ratio | - | 18.42% | - | - |
Equity / Assets | -25119.15% | 96.43% | 96.38% | 96.24% |
Book Value / Share | -0.13 | 41.67 | 10.15 | 10.23 |
NII Growth | - | - | -100% | - |
Dividend Payout | - | - | - | 29.69% |
Related:TDAC Dividend History·TDAC Revenue History·TDAC Price History·TDAC P/E History·TDAC Financial Ratios·TDAC Institutional Holders
TDAC SEC Filings & Documents
Translational Development Acquisition Corp. (TDAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
TDAC Frequently Asked Questions
Translational Development Acquisition Corp. (TDAC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Translational Development Acquisition Corp. (TDAC) saw revenue decline by 100.0% over the past year.
Yes, Translational Development Acquisition Corp. (TDAC) is profitable, generating $6.2M in net income for fiscal year 2025.
Dividend & Returns
Translational Development Acquisition Corp. (TDAC) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.
Industry Metrics
Translational Development Acquisition Corp. (TDAC) has a net interest margin (NIM) of N/A. NIM has been under pressure due to interest rate environment.
Translational Development Acquisition Corp. (TDAC) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.